LANGHORNE, Pa., Aug. 26, 2015 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (NASDAQ:ALQA) ("Alliqua" or "the Company"), a provider of advanced wound care products, today announced that company management will participate in the following investor conferences:
-
The Rodman & Renshaw 17th Annual Global Investment Conference in New York, New York
-
Brian Posner, Chief Financial Officer, and Brad Barton, Chief Operating Officer, will present on Wednesday, September 9th at 4:15 p.m. Eastern Time (ET).
-
Brian Posner, Chief Financial Officer, and Brad Barton, Chief Operating Officer, will present on Wednesday, September 9th at 4:15 p.m. Eastern Time (ET).
-
The 6th Annual Craig-Hallum Alpha Select Conference in New York, New York
- Brian Posner, Chief Financial Officer, and Nino Pionati, Chief Strategy and Marketing Officer, will present on Thursday, September 17th at 9:20 a.m. Eastern Time (ET).
Live webcasts of the conference presentations will be made available on the on the investor relations section of the Company's website at http://ir.alliqua.com. Archives of the conference webcasts will be available for replay following the events.
About Alliqua BioMedical, Inc.
Alliqua is a provider of advanced wound care solutions, committed to restoring tissue and rebuilding lives. Through its sales and distribution network, together with its proprietary products, Alliqua provides a suite of technological solutions to enhance the wound care practitioner's ability to deal with the challenges of healing both chronic and acute wounds.
Alliqua currently markets its line of dressings for wound care under the SilverSeal® and Hydress® brands, as well as the sorbion sachet S® and sorbion sana® wound care products, and its TheraBond 3D® advanced dressing which incorporates the TheraBond 3D® Antimicrobial Barrier Systems technology. The Company's Mist Therapy System® uses painless, noncontact low-frequency ultrasound to stimulate cells below the wound bed to promote the healing process. Alliqua also markets the human biologic wound care product Biovance®, as part of its licensing agreement with Celgene Cellular Therapeutics.
In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its hydrogel technology. Alliqua's electron beam production process, located at its 16,500 square foot Good Manufacturing Practice (GMP) manufacturing facility, allows Alliqua to custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries. The Company has locations in Langhorne, PA and Eden Prairie, MN.
For additional information, please visit http://www.alliqua.com. To receive future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts.
CONTACT: Investor Relations:
Westwicke Partners on behalf of Alliqua Biomedical, Inc.
Mike Piccinino, CFA +1-443-213-0500
[email protected]
